Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Significant Increase in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 52,800 shares, a growth of 58.6% from the February 28th total of 33,300 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 123,500 shares, the short-interest ratio is presently 0.4 days.

Shionogi & Co., Ltd. Stock Performance

Shares of OTCMKTS SGIOY traded down $0.07 during midday trading on Friday, reaching $7.59. 44,701 shares of the company traded hands, compared to its average volume of 134,492. The company has a market cap of $12.91 billion, a price-to-earnings ratio of 13.06, a PEG ratio of 2.37 and a beta of 0.23. The stock has a 50-day moving average price of $7.41 and a 200 day moving average price of $7.56. Shionogi & Co., Ltd. has a 52 week low of $6.22 and a 52 week high of $8.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.64 and a quick ratio of 7.01.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last released its quarterly earnings results on Friday, January 31st. The company reported $0.16 EPS for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. Sell-side analysts anticipate that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.